Aalami Amir Hossein, Shahriari Ali, Mazaheri Mohammad, Aalami Farnoosh, Amirabadi Amir, Sahebkar Amirhossein
Department of Nutrition and Integrative Physiology, College of Health, University of Utah, Salt Lake City, UT, USA; Department of Internal Medicine, Division of Nephrology, University of Utah, Salt Lake City, UT, USA.
Department of Internal Medicine, Faculty of Medicine, Mashhad Medical Sciences, Islamic Azad University, Mashhad, Iran.
Clin Biochem. 2023 Oct;120:110652. doi: 10.1016/j.clinbiochem.2023.110652. Epub 2023 Sep 25.
The tumor pyruvate kinase M2 isoform (tM2-PK) is a glycolytic enzyme isoform that is present on the surface of rapidly proliferating cancer cells. The objective of this investigation was to assess the efficacy of the tM2-PK measurement assay in detecting colorectal cancer (CRC) through the analysis of serum/plasma and stool samples obtained from patients.
The pooled diagnostic performance measures, including sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), the area under the curve (AUC), Q*index, and summary receiver-operating characteristic curve (SROC), were computed using the Meta-Disc V.1.4 and Comprehensive Meta-Analysis V.3.3 software. The statistical methods of I and chi-square were employed to assess the presence of heterogeneity. The estimation of publication bias was conducted through the implementation of Begg's rank correlation and Egger's regression asymmetry tests.
A total of 28 studies were found, involving 2900 participants (1560 cases and 1340 controls). The diagnostic accuracy of tM2-PK was calculated in CRC based on the pooled sensitivity of 83.70% (95% CI: 82.0% - 85.30%), specificity of 74.0% (95% CI: 72.0% - 76.0%), PLR of 4.432 (95% CI: 3.33 - 5.60), NLR of 0.187 (95% CI: 0.144 - 0.243), DOR of 30.182 (95% CI: 19.761 - 46.10) as well as AUC at 91.6%, and Q*-index at 85.0%. Publication bias was seen based on Begg's (p = 0.0006) and Egger's (p = 0.00015) tests.
The results demonstrate that tM2-PK exhibits promise as a fair marker for CTRC, with the potential to serve as a non-invasive biomarker.
肿瘤丙酮酸激酶M2亚型（tM2-PK）是一种糖酵解酶亚型，存在于快速增殖的癌细胞表面。本研究的目的是通过分析患者的血清/血浆和粪便样本，评估tM2-PK检测法在检测结直肠癌（CRC）方面的有效性。
使用Meta-Disc V.1.4和Comprehensive Meta-Analysis V.3.3软件计算汇总诊断性能指标，包括敏感性、特异性、阳性似然比（PLR）、阴性似然比（NLR）、诊断比值比（DOR）、曲线下面积（AUC）、Q*指数和汇总受试者工作特征曲线（SROC）。采用I²和卡方统计方法评估异质性的存在。通过实施Begg秩相关检验和Egger回归不对称检验来估计发表偏倚。
共检索到28项研究，涉及2900名参与者（1560例病例和1340例对照）。基于83.70%（95%CI：82.0% - 85.30%）的汇总敏感性、74.0%（95%CI：72.0% - 76.0%）的特异性、4.432（95%CI：3.33 - 5.60）的PLR、0.187（95%CI：0.144 - 0.243）的NLR、30.182（95%CI：19.761 - 46.10）的DOR以及91.6%的AUC和85.0%的Q*指数，计算出tM2-PK在CRC中的诊断准确性。基于Begg检验（p = 0.0006）和Egger检验（p = 0.00015）发现存在发表偏倚。
结果表明，tM2-PK有望成为一种良好的CTRC标志物，有可能作为一种非侵入性生物标志物。
